contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


a-new-study-supports-the-use-of-ubcr-rapid-in-the-follow-up-of-bladder-cancer-patients

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

IDL Diagnostics specializes in oncology and bacteriology. The company has a broad product portfolio, and develops, markets and sells blood and urine sample tests that are used by hospitals and clinics. The tests are intended to provide information for the detection of diseases such as urological cancers and typhoid fever. IDL Diagnostics targets patient groups in different parts of the world. The head office is in Stockholm.

IDL Diagnostics

The recently accepted scientific publication by Thorsten Ecke et.al. in the Urology Journal highlights the clinical utility of urine-based biomarkers compared to standard assays such as cystoscopy...

<div class="mfn-preamble"><p><strong>The recently accepted scientific publication by Thorsten Ecke et.al. in the Urology Journal highlights the clinical utility of urine-based biomarkers compared to standard assays such as cystoscopy and cytology for monitoring recurrent non-invasive bladder cancer. The study aims to evaluate the performance of UBC® Rapid in identifying patients with recurrent bladder cancer who were flagged as suspicious through cystoscopy.</strong></p></div><div class="mfn-body"><p>Recurrence of bladder cancer is common in patients who have undergone treatment. In this study, patients suspected of having recurrence based on cystoscopy were further evaluated with point-of-care tests. While cystoscopy remains the gold standard for bladder cancer follow-up, it is invasive and causes discomfort for patients. Using non-invasive biomarkers for follow-up is beneficial and might reduce the frequency of cystoscopies.</p><p>The study found that UBC® Rapid is more efficient at detecting recurrent bladder cancer compared to other point-of-care tests such as BTA stat® and NMP22®, which is consistent with previous findings. Furthermore, the clinical performance of UBC® Rapid is comparable to PCR-based Uromonitor® during the follow-up of bladder cancer patients.</p><p>“These results further strengthen the clinical applications of UBC® Rapid, not only as an aid in diagnosis but also in the surveillance of bladder cancer patients,” says Anders Hultman, CEO at AroCell.</p><p>The study includes 187 patients with suspicious cystoscopy findings during follow-up for non-muscle invasive bladder cancer (NIMBC). Out of these, 110 patients were confirmed to have bladder cancer by TUR-B (Transurethral resection), and all the point-of-care test markers were measured on these samples. The complete article's title and URL are provided below.</p><p>Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, CancerCheck® UBC® rapid VISUAL, and uromonitor® in comparison to cytology.</p><p><a rel="noopener" href="https://www.sciencedirect.com/science/article/abs/pii/S0090429524011130">https://www.sciencedirect.com/science/article/abs/pii/S0090429524011130</a></p></div><div class="mfn-footer mfn-contacts mfn-d7431fd42f58"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Anders Hultman, CEO<br>Phone: +46 (0) 8 799 67 50<br>E-mail:&nbsp;<a rel="noopener" href="mailto:anders.hultman@arocell.com">anders.hultman@arocell.com</a></p></div><div class="mfn-footer mfn-about mfn-3400a8a23fe3"><p><strong class="mfn-heading-1">About AroCell</strong></p><hr><p>AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; <a rel="noopener" href="https://arocell.us12.list-manage.com/track/click?u=afc00720b3f14956d7aa211ee&amp;id=b0c0db8833&amp;e=1eac5f4714">www.arocell.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/3c421458-4c29-4262-8fac-d4b9e5fd46ab/a-new-study-supports-the-use-of-ubc-r-rapid-in-the-follow-up-of-bladder-cancer-patients.pdf" class="mfn-generated mfn-primary">A new study supports the use of UBC® Rapid in the follow-up of bladder cancer patients</a></p></div>

A new study supports the use of UBC® Rapid in the follow-up of bladder cancer patients